BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 33976305)

  • 1. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
    Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
    J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
    Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
    BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    Jiang H; Xu S; Chen C
    BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
    Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
    Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight-gene signature predicts recurrence in lung adenocarcinoma.
    Zhang Y; Fan Q; Guo Y; Zhu K
    Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a four-gene panel predicting overall survival for lung adenocarcinoma.
    Li C; Long Q; Zhang D; Li J; Zhang X
    BMC Cancer; 2020 Dec; 20(1):1198. PubMed ID: 33287749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
    Zhou J; Wang X; Li Z; Jiang R
    FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering N
    Zhu J; Wang M; Hu D
    Biomed Res Int; 2020; 2020():2514230. PubMed ID: 32258108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
    Zhou J; Wang X; Li Z; Jiang R
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
    Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
    J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases.
    Zhou Y; Gao S; Yang R; Du C; Wang Y; Wu Y
    Transl Lung Cancer Res; 2022 Jul; 11(7):1479-1496. PubMed ID: 35958325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.